Oxomemazine

Summary

Oxomemazine (CHEMBL2104734) is a phase-3 clinical-stage small molecule (ATC R06AD08); indicated across 2 conditions including allergic disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: R06AD08
• Indications: 2 conditions
• Chemistry: 330.4 Da · C18H22N2O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104734
Name	Oxomemazine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	19396
ATC	R06AD08
Molecular formula	C18H22N2O2S
Molecular weight	330.4
InChIKey	QTQPVLDZQVPLGV-UHFFFAOYSA-N

SMILES: CC(CN1C2=CC=CC=C2S(=O)(=O)C3=CC=CC=C31)CN(C)C

IUPAC name: 3-(5,5-dioxophenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine

Also known as: Doxergan, Dysedon, Exe-top, Imakol, Oplex, Oxomemazina, Oxomemazine, RP 6847, RP-6847, OXOMEMAZINE

Parent form; salt/anhydrous children: CHEMBL3187201

Patent coverage: 160 distinct patent families (559 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 550 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
allergic disease	3	MONDO:0005271	MONDO:0005271

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).